从边缘到核心:边缘区样B细胞成为克拉屈滨治疗多发性硬化的关键靶点
该48个月纵向研究对36例完成2个年度疗程的复发缓解型多发性硬化患者用高参数流式细胞术追踪B细胞亚群,并行横断面比较16例未治疗患者与16名健康供者。克拉屈滨持续深度耗竭记忆B细胞,边缘区样B细胞丢失最深最持久;该亚群是多功能促炎细胞因子和IgM的最强产生者,在患者中显著增强。
要点
- 克拉屈滨对边缘区样B细胞造成最深、最持久的耗竭。
- 边缘区样B细胞是多功能促炎因子和IgM的主要来源。
- 该亚群高表达CD1c和CD1d,提示脂质抗原提呈特化。
核心结论
- 边缘区样B细胞是多发性硬化中占主导的多功能炎症亚群,也是克拉屈滨优先作用的药理靶点。
- 该致病记忆池的持续减少及后续炎症性较低B细胞的重建,为克拉屈滨持久临床获益提供机制基础。
- 边缘区样B细胞可 nominated 为治疗反应生物标志物和治疗靶点。
研究设计与样本
- 48个月纵向研究纳入36例完成2个年度疗程的复发缓解型多发性硬化患者,用高参数流式细胞术追踪B细胞亚群动态。
- 平行横断面分析对16例未治疗患者和16名健康供者的B细胞进行多功能细胞因子产生和关键表面标志物分析。
主要发现
- 克拉屈滨诱导记忆B细胞深刻、持续耗竭,其中边缘区样细胞丢失最深、最持久,同时过渡型和初始群体重建。
- 边缘区样B细胞是多功能促炎细胞因子GM-CSF、IL-6、TNF-α和IgM的最强产生者,该能力在患者中较健康供者显著增强。
- 边缘区样B细胞表达最高水平的CD1c和CD1d,符合脂质抗原提呈特化。
临床怎么用
- 可将边缘区样B细胞的持续减少作为克拉屈滨治疗反应的潜在生物标志物。
- 针对边缘区样B细胞的非经典脂质抗原提呈和IgM分泌功能,可能为多发性硬化提供新的治疗靶点。
局限性
- 纵向研究样本量为36例,横断面比较为16例未治疗患者和16名健康供者,样本量有限。
- 研究未报告长期临床结局与B细胞亚群动态的直接关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long-term impact on distinct B-cell subsets is not fully understood. This study aimed to define cladribine's longitudinal effects on B-cell subsets and characterize their inflammatory properties. METHODS: We conducted a 48-month longitudinal study of 36 persons with relapsing-remitting MS treated with cladribine who had completed 2 annual treatment cycles, using high-parameter flow cytometry to track B-cell subset dynamics. In a parallel cross-sectional analysis, B cells from 16 untreated patients and 16 healthy donors were profiled for polyfunctional cytokine production granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and key surface markers. RESULTS: Cladribine induced profound, sustained depletion of memory B cells, with marginal zone-like (MZ-like) cells showing the deepest and most persistent loss, alongside reconstitution of transitional and naïve populations. Functionally, MZ-like B cells were the most potent polyfunctional producers of proinflammatory cytokines and immunoglobulin M (IgM), a capacity significantly enhanced in persons with MS compared to healthy donors, and expressed the highest levels of CD1c and CD1d, consistent with specialization in lipid antigen presentation. INTERPRETATION: MZ-like B cells are a dominant, polyfunctional inflammatory subset in MS, equipped for non-canonical lipid antigen presentation and IgM secretion. They represent a preferential pharmacological target of cladribine. Sustained reduction of this pathogenic memory pool, followed by repopulation with less inflammatory B cells, offers a mechanistic basis for cladribine's durable clinical benefit and nominates MZ-like cells as biomarkers of response and therapeutic targets. ANN NEUROL 2026;100:808-823.
引用
- Pirronello M, Picozza M, Guerrera G, et al. From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis. Ann Neurol. 2026. PMID: 42312812. doi:10.1002/ana.78277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。